Biopharmaceutical start-up BioAge Labs is developing a weight loss drug for older adults known as azelaprag, which is intended to be taken orally along with other weight loss drugs. According to ...

Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at ...

BioAge shifted the drug’s focus to obesity after encouraging preclinical tests of the molecule dosed in combination with Lilly’s Zepbound showed greater weight loss than Zepbound alone.

BioAge’s NLRP3 inhibitor, code-named BGE-100, is on track for an investigational new drug application in the second half of 2025. Fortney is BioAge’s largest shareholder with a 6.7% post-IPO ...

BioAge Labs has garnered the support of Eli Lilly to run a trial combining a muscle regeneration therapy with the Big Pharma’s tirzepatide for healthier weight loss. While no financial details ...

(Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor ...

BioAge Labs will co-administer its muscle loss drug azelaprag with Mounjaro to treat obesity as part of a clinical trial in partnership with Mounjaro maker Eli Lilly’s development arm, Chorus ...

The surging popularity of weight-loss drugs, expected to be a $150 billion market by early 2030s, has whetted investor appetite in companies looking to tap into the boom. BioAge priced its ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.